Fingerprint
Dive into the research topics of 'Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study
John C. Araujo, Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, Géralyn C. Trudel, Prashni Paliwal, Shruti Agrawal, Christopher J. Logothetis
Research output: Contribution to journal › Article › peer-review
124
Scopus
citations